Investors > Overview

Acacia Pharma is a commercial stage biopharmaceuticall group focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and procedural sedation, and has two approved products and a late-stage development candidate in its portfolio designed to meet those needs.

Barhemsys®  was approved in the US in February 2020.

Byfavo® was approved in the US in July 2020.  Acacia Pharma’s rights to further develop and commercialize Byfavo® are in-licensed from Paion UK Limited pursuant to an assignment from Cosmo Technologies Limited for the US market. 

See our marketed products here.

The Group’s pipeline also includes APD403 for chemotherapy induced nausea & vomiting (CINV). APD403 is based on the selective dopamine antagonist amisulpride, the same active ingredient as in Barhemsys®. It is being developed in both intravenous and oral form and has successfully completed Phase 2 testing in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its own commercial infrastructure in the US through which it markets and sells its products directly.

The Company’s management team and Board have extensive experience in the discovery, development and commercialization of hospital pharmaceutical products.

Acacia Pharma has offices in Cambridge, UK and Indianapolis, IN, USA, and is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.